Reward Mechanisms in Obesity

NCT03347890 on ClinicalTrials.gov · last registry update 2021-04-30

Finished 18 March 2020, after enrolling 70 people. Primary outcome, as filed: Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Zoltan Pataky
Sponsor type: Other
Enrollment: 70
Started: 2018-03-05
Primary completion: 2020-03-18 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.